Blood enzymes and oxidative stress in chronic kidney disease: A cross sectional study

Annals of Clinical and Laboratory Science

Volumn 41, Issue 4, 2011, Pages 331-339

  Johnson Davis, Kamisha L ^a   Fernelius, Colby ^b   Eliason, Nathan B ^c   Wilson, Andrew ^d   Beddhu, Srinivasan ^a   Roberts, William L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b MADIGAN ARMY MEDICAL CENTER   (United States)

^c Ivinson Memorial Hospital   (United States)

^d ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

Antioxidant; Atherosclerosis; Chronic kidney disease; Hemodialysis; Oxidative stress

Indexed keywords

ARYLDIALKYLPHOSPHATASE; GLUTATHIONE PEROXIDASE; ISOPROSTANE DERIVATIVE; OXIDIZED LOW DENSITY LIPOPROTEIN; SELENIUM;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; IN VIVO STUDY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; GLUTATHIONE PEROXIDASE; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; OXIDANTS; OXIDATIVE STRESS; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84855387581     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Scoggins RB, Harlan WR Jr. Cutaneous manifestations of hyperlipidemia and uremia. Postgrad Med 1967;41:537-545.
2. Attman P-O, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia -relation to renal function and dialysis. Nephron 1991;57:401-410.
3. Attman P-O, Alaupovic P. Lipid abnormalities in chronic renal insufficiency. Kidney Int 1991;39:S16-S23.
4. Bagdade JD, Porte D Jr, Bierman EL. Hypertriglyceridemia. A metabolic consequence of chronic renal failure. N Engl J Med 1968;279:181-185.
5. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-1538.
6. Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr Opin Nephrol Hypertens 2003;12:593-598.
7. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thévenin M, Jaudon MC, Zingraff J, Verger C, Jungers P, Descamps-Latscha B. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996;21:845-53.
8. Chauhan DP, Gupta PH, Nampoothiri MR, Singhal PC, Chugh KS, Nair CR. Determination of erythrocyte superoxide dismutase, catalase, glucose-6-phosphate dehydrogenase, reduced glutathione and malonyldialdehyde in uremia. Clin Chim Acta 1982;123:153-159.
9. Chu FF, Esworthy S, Doroshow JH, Doan K, Liu XF. Expression of plasma glutathione peroxidase in human liver in addition to kidney, heart, lung, and breast in humans and rodents. Blood. 1992;79:3233-3238.
10. Avissar N, Ornt DB, Yagil Y, Horowitz S, Watkins RH, Kerl EA, Takahashi K, Palmer IS, Cohen HJ. Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J Physiol 1994;266:C367-C375.
11. Zachara BA, Gromadzinska J, Wasowicz W, Zbróg Z. Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: A review. Acta Biochim Pol 2006;53:663-677.
12. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998;9:2082-2088.
13. Paragh G, Asztalos L, Seres I, Balogh Z, Löcsey L, Kárpáti I, Mátyus J, Katona E, Harangi M, Kakuk G. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 1999;83:126-131.
14. Roxborough HE, Mercer C, McMaster D, Maxwell AP, Young IS. Plasma glutathione peroxidase activity is reduced in haemodialysis patients. Nephron 1999;81:278-281.
15. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994;45:876-883.
16. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994;46:869-876.
17. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ II. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism, Proc. Natl. Acad. Sci. USA 1990;87:9383-9387.
18. Stein CM, Tanner SB, Awad JA, Roberts LJ 2nd, Morrow JD. Evidence of free radical-medicated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996;39:1146-1150.
19. Furlong CE, Richter RJ, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988;43:230-238.
20. Andersen HR, Nielsen JB, Nielsen F, Grandjean P. Antioxidative enzyme activities in human erythrocytes. Clin Chem 1997;43:562-568.
21. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER. Oxidative stress in haemodialysis. Q J Med 1994;87:679-683.
22. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low density lipoprotein that increases its atherogenicity. N Engl J Med 1989;320:915-923.
23. Steinberg D. Role of oxidized LDL and antioxidants in atherosclerosis. Adv Exp Med Biol 1995;369:39-48.
24. Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, Takano T. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 1996:37:45-53.
25. Practico D. F2-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atheroscler 1999;147:1-10.
26. Patrono C, Fitzgerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Atherioscler Thromb Vasc Biol 1997;17:2309-2315.
27. Montuschi P, Barnes PJ, Roberts LJ 2nd. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004;18:1791-1800.
28. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ 2nd. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995;332:1198-12063.
29. Gopaul NK, Anggård EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J. Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 1995;368:225-229.
30. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001;59:1960-1966.
31. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, Shyr Y, Himmelfarb J. Plasma F2-isoprostanes levels are elevated in chronic hemodialysis patients. Clin Nephrol 2002;58:190-197.
32. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973;179:588-590.
33. Cohen HJ, Chovaniec ME, Mistretta D, Baker SS. Selenium repletion and glutathione peroxidase - differential effects on plasma and red blood cell enzyme activity. Am J Clin Nutr 1985;41:735-747.
34. Lockitch G. Selenium: Clinical significance and analytical concepts. Clin Rev Clin Lab Sci 1989; 27:483-541.
35. Kallistratos G, Evangelou A, Seferiadis K, Vezyraki P, Barboutis K. Selenium and haemodialysis: serum selenium levels in healthy persons, non-cancer and cancer patients with chronic renal failure. Nephron 1985;41:217-222.
36. Dworkin B, Weseley S, Rosenthal WS, Schwartz EM, Weiss L. Diminished blood selenium levels in renal failure patients on dialysis: correlation with nutritional status. Am J Med Sci 1987;293:6-12.
37. Tsukamoto Y, Iwamami S, Marumo F. Disturbance of trace element concentrations in plasma of patients with chronic renal failure. Nephron 1980;26:174-179.
38. Richard MJ, Arnaud J, Jurkovitz C, Hachache T, Meftahi H, Laporte F, Foret M, Favier A, Cordonnier D. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 1991;57:10-15.
39. Zachara BA, Adamowicz A, Trafikowsha U, Pilecki A, Manitius J. Decreased plasma glutathione peroxidase activity in uraemic patients. Nephron 2000;84:278-281.
40. Yoshimura S, Suemizu H, Nomoto Y, Sakai H, Katsuoka Y, Kawamura N, Moriuchi T. Plasma glutathione peroxidase deficiency caused by renal dysfunction. Nephron 1996;73:207-211.
41. De Vega L, Férnandez RP, Mateo MC, Bustamante JB, Herrero AM, Munguira EB. Glutathione determination and a study of the activity of glutathione-peroxidase, glutathione-transferase, and glutathione-reductase in renal transplants. Ren Fail 2002;24:421-432.
42. Sommerburg O, Grune T, Ehrich JH, Siems WG. Adaptation of glutathione-peroxidase activity to oxidative stress occurs in children but not in adults patients with end-stage renal failure undergoing hemodialysis. Clin Nephrol 2002;58:S31-S36.
43. Aviram M, Rosenblat M. Paraoxonase 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004;37:1304-1316.
44. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991;86:193-199.
45. Jurectić D, Tadijanović M, Rekić B, Simeon-Rudolf V, Reiner E, Baricić M. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat Med J 2001;42:146-150.